» Articles » PMID: 34032853

Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID-19

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2021 May 25
PMID 34032853
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Male sex is a risk factor for developing severe COVID-19 illness. It is not known whether sex hormones contribute to this predisposition.

Objective: To investigate the association of concentrations of serum testosterone, estradiol, and insulinlike growth factor 1 (IGF-1, concentrations of which are regulated by sex hormone signaling) with COVID-19 severity.

Design, Setting, And Participants: This prospective cohort study was conducted using serum samples collected from consecutive patients who presented from March through May 2020 to the Barnes Jewish Hospital in St Louis, Missouri, with COVID-19 (diagnosed using nasopharyngeal swabs).

Exposures: Testosterone, estradiol, and IGF-1 concentrations were measured at the time of presentation (ie, day 0) and at days 3, 7, 14, and 28 after admission (if the patient remained hospitalized).

Main Outcomes And Measures: Baseline hormone concentrations were compared among patients who had severe COVID-19 vs those with milder COVID-19 illness. RNA sequencing was performed on circulating mononuclear cells to understand the mechanistic association of altered circulating hormone concentrations with cellular signaling pathways.

Results: Among 152 patients (90 [59.2%] men; 62 [40.8%] women; mean [SD] age, 63 [16] years), 143 patients (94.1%) were hospitalized. Among 66 men with severe COVID-19, median [interquartile range] testosterone concentrations were lower at day 0 (53 [18 to 114] ng/dL vs 151 [95 to 217] ng/dL; P = .01) and day 3 (19 [6 to 68] ng/dL vs 111 [49 to 274] ng/dL; P = .006) compared with 24 men with milder disease. Testosterone concentrations were inversely associated with concentrations of interleukin 6 (β = -0.43; 95% CI, -0.52 to -0.17; P < .001), C-reactive protein (β = -0.38; 95% CI, -0.78 to -0.16; P = .004), interleukin 1 receptor antagonist (β = -0.29; 95% CI, -0.64 to -0.06; P = .02), hepatocyte growth factor (β = -0.46; 95% CI, -0.69 to -0.25; P < .001), and interferon γ-inducible protein 10 (β = -0.32; 95% CI, -0.62 to -0.10; P = .007). Estradiol and IGF-1 concentrations were not associated with COVID-19 severity in men. Testosterone, estradiol, and IGF-1 concentrations were similar in women with and without severe COVID-19. Gene set enrichment analysis revealed upregulated hormone signaling pathways in CD14+CD16- (ie, classical) monocytes and CD14-CD16+ (ie, nonclassical) monocytes in male patients with COVID-19 who needed intensive care unit treatment vs those who did not.

Conclusions And Relevance: In this single-center cohort study of patients with COVID-19, lower testosterone concentrations during hospitalization were associated with increased disease severity and inflammation in men. Hormone signaling pathways in monocytes did not parallel serum hormone concentrations, and further investigation is required to understand their pathophysiologic association with COVID-19.

Citing Articles

Effect of SARS-CoV-2 infection on sperm telomere length.

Soares M, de Carvalho R, Dos Santos Cirino H, Martins R, Furtado C, Santana B J Assist Reprod Genet. 2025; .

PMID: 39934464 DOI: 10.1007/s10815-025-03408-6.


Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers.

Sun J, Peters M, Yu L, Vijay V, Bidarimath M, Agrawal M Metabolomics. 2024; 21(1):3.

PMID: 39636373 DOI: 10.1007/s11306-024-02195-y.


Hypopituitarism and COVID-19.

Carosi G, Cremaschi A, Giavoli C, Ferrante E, Mantovani G Pituitary. 2024; 27(6):925-934.

PMID: 39560821 DOI: 10.1007/s11102-024-01463-3.


Increased interleukin-6 levels are associated with atrioventricular conduction delay in severe COVID-19 patients.

Accioli R, Lazzerini P, Salvini V, Cartocci A, Verrengia D, Marzotti T J Arrhythm. 2024; 40(5):1137-1148.

PMID: 39416238 PMC: 11474750. DOI: 10.1002/joa3.13114.


Retrospective Analysis of the Effect of Postmenopausal Women Medications on SARS-CoV-2 Infection Progression.

Cocetta V, Zorzi M, Bejor S, Cesta M, De Pizzol M, Theurillat J Life (Basel). 2024; 14(9).

PMID: 39337891 PMC: 11433321. DOI: 10.3390/life14091107.


References
1.
Van den Berghe G, Weekers F, BAXTER R, Wouters P, Iranmanesh A, Bouillon R . Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab. 2001; 86(7):3217-26. DOI: 10.1210/jcem.86.7.7680. View

2.
Koskinen M, Carpen O, Honkanen V, Seppanen M, Miettinen P, Tuominen J . Androgen deprivation and SARS-CoV-2 in men with prostate cancer. Ann Oncol. 2020; 31(10):1417-1418. PMC: 7323668. DOI: 10.1016/j.annonc.2020.06.015. View

3.
Heffernan D, Dossett L, Lightfoot M, Fremont R, Ware L, Sawyer R . Gender and acute respiratory distress syndrome in critically injured adults: a prospective study. J Trauma. 2011; 71(4):878-83. PMC: 3201740. DOI: 10.1097/TA.0b013e31822c0d31. View

4.
Simpson E, Clyne C, Rubin G, Boon W, Robertson K, Britt K . Aromatase--a brief overview. Annu Rev Physiol. 2002; 64:93-127. DOI: 10.1146/annurev.physiol.64.081601.142703. View

5.
Ahasic A, Zhai R, Su L, Zhao Y, Aronis K, Thompson B . IGF1 and IGFBP3 in acute respiratory distress syndrome. Eur J Endocrinol. 2011; 166(1):121-9. PMC: 3757506. DOI: 10.1530/EJE-11-0778. View